Business
Marker Therapeutics Awarded $13.1 Million Grant from the Cancer Prevention and Research Institute of Texas
HOUSTON, Aug. 19, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of
About this update from Marker Therapeutics, Inc.
[{"type":"text","content":"HOUSTON, Aug. 19, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that the Company received notice of a Product Development Research award totaling approximately $13.1 million from the Cancer Prevention and Research Institute of Texas (CPRIT) to support the Company's Phase 2 clinical trial of its lead MultiTAA-specific T cell product MT-401. \n\n \n \n \n \n \n \n\n \nThe CPRIT award is intended to support the adjuvant arm of the Company's Phase 2 clinical trial evaluating MT-401 when given as an adjuvant therapy to patients with acute myeloid leukemia (AML) following a hematopoietic stem cell transplant. The primary objectives of the adjuvant arm of the trial are to evaluate relapse-free survival after MT-401 treatment when compared with a randomized control group. \n\"We are honored to have been approved by CPRIT for this award which provides additional capital to support the clinical development of MT-401 and external validation of our technology from experts in the field who conducted business and scientific diligence on behalf of CPRIT,\" said Peter L. Hoang, President & CEO of Marker Therapeutics. \"Our MultiTAA-specific T cell therapy approach has shown encouraging results in post-transplant AML in clinical studies, and we are pleased to advance the clinical development of MT-401 in our Phase 2 trial.\" \nAbout the Cancer Prevention and Research Institute of Texas\nTo date, CPRIT has awarded $2.9 billion in grants to Texas research institutions and organizations through its academic research, prevention and product development research programs. CPRIT has recruited 237 distinguished researchers, supported the establishment, expansion or relocation of 43 companies to Texas and generated over $5.7 billion in additional public and private investment. CPRIT funding has advanced scientific and clinical knowledge and provided 7.4 million life-saving cancer prevention and early detection services reaching Texans from all 254 counties. On November 5, 2019, Texas voters overwhelmingly approved a constitutional amendment to provide an additional $3 billion to CPRIT for a total $6 billion investment in cancer...